Cathelicidin LL-37: An antimicrobial peptide with a role in inflammatory skin disease

Annals of Dermatology

Volumn 24, Issue 2, 2012, Pages 126-135

  Reinholz, Markus ^a   Ruzicka, Thomas ^a   Schauber, Jürgen ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

Atopic dermatitis; Cathelicidin LL 37; Innate immunity; Psoriasis; Rosacea; Vitamin D

Indexed keywords

EID: 84860610161     PISSN: 10139087     EISSN: None     Source Type: Journal    
DOI: 10.5021/ad.2012.24.2.126     Document Type: Review

References (80)

1. Nestle FO, Di Meglio P, Qin JZ, Nickoloff BJ. Skin immune sentinels in health and disease. Nat Rev Immunol 2009;9:679-691.
2. Pasupuleti M, Schmidtchen A, Malmsten M. Antimicrobial peptides: key components of the innate immune system. Crit Rev Biotechnol 2011. [Epub ahead of print]
3. Yeaman MR, Yount NY. Mechanisms of antimicrobial peptide action and resistance. Pharmacol Rev 2003;55:27-55. (Pubitemid 36268398)
4. Schauber J, Gallo RL. Expanding the roles of antimicrobial peptides in skin: alarming and arming keratinocytes. J Invest Dermatol 2007;127:510-512.
5. Braff MH, Zaiou M, Fierer J, Nizet V, Gallo RL. Keratinocyte production of cathelicidin provides direct activity against bacterial skin pathogens. Infect Immun 2005;73:6771-6781. (Pubitemid 41368844)
6. Murakami M, Ohtake T, Dorschner RA, Schittek B, Garbe C, Gallo RL. Cathelicidin anti-microbial peptide expression in sweat, an innate defense system for the skin. J Invest Dermatol 2002;119:1090-1095. (Pubitemid 35434172)
7. Dorschner RA, Pestonjamasp VK, Tamakuwala S, Ohtake T, Rudisill J, Nizet V, et al. Cutaneous injury induces the release of cathelicidin anti-microbial peptides active against group A Streptococcus. J Invest Dermatol 2001;117:91-97. (Pubitemid 32652444)
8. Antal AS, Dombrowski Y, Koglin S, Ruzicka T, Schauber J. Impact of vitamin D3 on cutaneous immunity and antimicrobial peptide expression. Dermatoendocrinol 2011;3:18-22.
9. Braff MH, Gallo RL. Antimicrobial peptides: an essential component of the skin defensive barrier. Curr Top Microbiol Immunol 2006;306:91-110. (Pubitemid 47400319)
10. Zhang G, Ross CR, Blecha F. Porcine antimicrobial peptides: new prospects for ancient molecules of host defense. Vet Res 2000;31:277-296.
11. Wang Z, Wang G. APD: the antimicrobial peptide database. Nucleic Acids Res 2004;32(Database issue):D590-592. (Pubitemid 38081727)
12. Peric M, Koglin S, Kim SM, Morizane S, Besch R, Prinz JC, et al. IL-17A enhances vitamin D3-induced expression of cathelicidin antimicrobial peptide in human keratinocytes. J Immunol 2008;181:8504-8512.
13. Harder J, Bartels J, Christophers E, Schroder JM. Isolation and characterization of human beta-defensin-3, a novel human inducible peptide antibiotic. J Biol Chem 2001;276:5707-5713.
14. Schauber J, Dorschner RA, Coda AB, Büchau AS, Liu PT, Kiken D, et al. Injury enhances TLR2 function and antimicrobial peptide expression through a vitamin D-dependent mechanism. J Clin Invest 2007;117:803-811. Epub 2007 Feb. 8. (Pubitemid 46348539)
15. Wolk K, Witte E, Wallace E, Döcke WD, Kunz S, Asadullah K, et al. L-22 regulates the expression of genes responsible for antimicrobial defense, cellular differentiation, and mobility in keratinocytes: a potential role in psoriasis. Eur J Immunol 2006;36:1309-1323.
16. Yamasaki K, Schauber J, Coda A, Lin H, Dorschner RA, Schechter NM, et al. Kallikrein-mediated proteolysis regulates the antimicrobial effects of cathelicidins in skin. FASEB J 2006;20:2068-2080. (Pubitemid 44953906)
17. Michaelson D, Rayner J, Couto M, Ganz T. Cationic defensins arise from charge-neutralized propeptides: a mechanism for avoiding leukocyte autocytotoxicity? J Leukoc Biol 1992;51:634-639.
18. Selsted ME, Ouellette AJ. Mammalian defensins in the antimicrobial immune response. Nat Immunol 2005;6:551-557. (Pubitemid 41710724)
19. Zaiou M, Gallo RL. Cathelicidins, essential gene-encoded mammalian antibiotics. J Mol Med (Berl) 2002;80:549-561.
20. Harder J, Siebert R, Zhang Y, Matthiesen P, Christophers E, Schlegelberger B, et al. Mapping of the gene encoding human beta-defensin-2 (DEFB2) to chromosome region 8p22-p23.1. Genomics 1997;46:472-475. (Pubitemid 28063297)
21. Schröder JM, Harder J. Human beta-defensin-2. Int J Biochem Cell Biol 1999;31:645-651. (Pubitemid 29248873)
22. Gläser R, Navid F, Schuller W, Jantschitsch C, Harder J, Schröder JM, et al. UV-B radiation induces the expression of antimicrobial peptides in human keratinocytes in vitro and in vivo. J Allergy Clin Immunol 2009;123:1117-1123.
23. Zhao C, Wang I, Lehrer RI. Widespread expression of betadefensin hBD-1 in human secretory glands and epithelial cells. FEBS Lett 1996;396:319-322. (Pubitemid 26377848)
24. Cowland JB, Johnsen AH, Borregaard N. hCAP-18, a cathelin/pro-bactenecin- like protein of human neutrophil specific granules. FEBS Lett 1995;368:173-176.
25. Larrick JW, Hirata M, Zhong J, Wright SC. Anti-microbial activity of human CAP18 peptides. Immunotechnology 1995;1:65-72.
26. Gudmundsson GH, Agerberth B, Odeberg J, Bergman T, Olsson B, Salcedo R. The human gene FALL39 and processing of the cathelin precursor to the antibacterial peptide LL-37 in granulocytes. Eur J Biochem 1996;238:325-332. (Pubitemid 26188246)
27. López-García B, Lee PH, Yamasaki K, Gallo RL. Anti-fungal activity of cathelicidins and their potential role in Candida albicans skin infection. J Invest Dermatol 2005;125:108-115. (Pubitemid 40981431)
28. López-García B, Lee PH, Gallo RL. Expression and potential function of cathelicidin antimicrobial peptides in dermatophytosis and tinea versicolor. J Antimicrob Chemother 2006;57:877-882.
29. Tsai PW, Yang CY, Chang HT, Lan CY. Human antimicrobial peptide LL-37 inhibits adhesion of Candida albicans by interacting with yeast cell-wall carbohydrates. PLoS One 2011;6:e17755.
30. Braff MH, Hawkins MA, Di Nardo A, Lopez-Garcia B, Howell MD, Wong C, et al. Structure-function relationships among human cathelicidin peptides: dissociation of antimicrobial properties from host immunostimulatory activities. J Immunol 2005;174:4271-4278. (Pubitemid 40396008)
31. Zheng Y, Niyonsaba F, Ushio H, Nagaoka I, Ikeda S, Okumura K, et al. Cathelicidin LL-37 induces the generation of reactive oxygen species and release of human alphadefensins from neutrophils. Br J Dermatol 2007;157:1124-1131. (Pubitemid 350115677)
32. Yu J, Mookherjee N, Wee K, Bowdish DM, Pistolic J, Li Y, et al. Host defense peptide LL-37, in synergy with inflammatory mediator IL-1beta, augments immune responses by multiple pathways. J Immunol 2007;179:7684-7691.
33. Koczulla R, von Degenfeld G, Kupatt C, Krötz F, Zahler S, Gloe T, et al. An angiogenic role for the human peptide antibiotic LL-37/hCAP-18. J Clin Invest 2003;111:1665-1672. (Pubitemid 38057748)
34. Schauber J, Gallo RL. Antimicrobial peptides and the skin immune defense system. J Allergy Clin Immunol 2008;122:261-266.
35. Oppenheim JJ, Tewary P, de la Rosa G, Yang D. Alarmins initiate host defense. Adv Exp Med Biol 2007;601:185-194.
36. Tomasinsig L, Pizzirani C, Skerlavaj B, Pellegatti P, Gulinelli S, Tossi A, et al. The human cathelicidin LL-37 modulates the activities of the P2X7 receptor in a structure-dependent manner. J Biol Chem 2008;283:30471-30481.
37. Di Nardo A, Braff MH, Taylor KR, Na C, Granstein RD, McInturff JE, et al. Cathelicidin antimicrobial peptides block dendritic cell TLR4 activation and allergic contact sensitization. J Immunol 2007;178:1829-1834. (Pubitemid 46154655)
38. Tokumaru S, Sayama K, Shirakata Y, Komatsuzawa H, Ouhara K, Hanakawa Y, et al. Induction of keratinocyte migration via transactivation of the epidermal growth factor receptor by the antimicrobial peptide LL-37. J Immunol 2005;175:4662-4668. (Pubitemid 41362007)
39. Bieber T. Atopic dermatitis. N Engl J Med 2008;358:1483-1494.
40. Ong PY, Ohtake T, Brandt C, Strickland I, Boguniewicz M, Ganz T, et al. Endogenous antimicrobial peptides and skin infections in atopic dermatitis. N Engl J Med 2002;347:1151-1160.
41. Mallbris L, Carlén L, Wei T, Heilborn J, Nilsson MF, Granath F, et al. Injury downregulates the expression of the human cathelicidin protein hCAP18/LL-37 in atopic dermatitis. Exp Dermatol 2010;19:442-449. Epub 2009 Jul. 23.
42. Howell MD, Gallo RL, Boguniewicz M, Jones JF, Wong C, Streib JE, et al. Cytokine milieu of atopic dermatitis skin subverts the innate immune response to vaccinia virus. Immunity 2006;24:341-348.
43. Jensen JM, Ahrens K, Meingassner J, Scherer A, Bräutigam M, Stütz A, et al. Differential suppression of epidermal antimicrobial protein expression in atopic dermatitis and in EFAD mice by pimecrolimus compared to corticosteroids. Exp Dermatol 2011;20:783-788.
44. Ballardini N, Johansson C, Lilja G, Lindh M, Linde Y, Scheynius A, et al. Enhanced expression of the antimicrobial peptide LL-37 in lesional skin of adults with atopic eczema. Br J Dermatol 2009;161:40-47.
45. Goo J, Ji JH, Jeon H, Kim MJ, Jeon SY, Cho MY, et al. Expression of antimicrobial peptides such as LL-37 and hBD-2 in nonlesional skin of atopic individuals. Pediatr Dermatol 2010;27:341-348.
46. Leung TF, Ching KW, Kong AP, Wong GW, Chan JC, Hon KL. Circulating LL-37 is a biomarker for eczema severity in children. J Eur Acad Dermatol Venereol 2012;26:518-522.
47. Howell MD, Wollenberg A, Gallo RL, Flaig M, Streib JE, Wong C, et al. Cathelicidin deficiency predisposes to eczema herpeticum. J Allergy Clin Immunol 2006;117:836-841.
48. Hata TR, Kotol P, Boguniewicz M, Taylor P, Paik A, Jackson M, et al. History of eczema herpeticum is associated with the inability to induce human β-defensin (HBD)-2, HBD-3 and cathelicidin in the skin of patients with atopic dermatitis. Br J Dermatol 2010;163:659-661.
49. Chosidow O, Cribier B. Epidemiology of rosacea: updated data. Ann Dermatol Venereol 2011;138 Suppl 2:S124-S128.
50. Yamasaki K, Di Nardo A, Bardan A, Murakami M, Ohtake T, Coda A, et al. Increased serine protease activity and cathelicidin promotes skin inflammation in rosacea. Nat Med 2007;13:975-980. (Pubitemid 47222043)
51. Murakami M, Lopez-Garcia B, Braff M, Dorschner RA, Gallo RL. Postsecretory processing generates multiple cathelicidins for enhanced topical antimicrobial defense. J Immunol 2004;172:3070-3077. (Pubitemid 38263696)
52. Meyer-Hoffert U, Schröder JM. Epidermal proteases in the pathogenesis of rosacea. J Investig Dermatol Symp Proc 2011;15:16-23.
53. Morizane S, Yamasaki K, Kabigting FD, Gallo RL. Kallikrein expression and cathelicidin processing are independently controlled in keratinocytes by calcium, vitamin D (3), and retinoic acid. J Invest Dermatol 2010;130:1297-1306.
54. Schauber J, Gallo RL. The vitamin D pathway: a new target for control of the skin's immune response? Exp Dermatol 2008;17:633-639. (Pubitemid 352044354)
55. Peric M, Lehmann B, Vashina G, Dombrowski Y, Koglin S, Meurer M, et al. UV-B-triggered induction of vitamin D3 metabolism differentially affects antimicrobial peptide expression in keratinocytes. J Allergy Clin Immunol 2010;125:746-749.
56. Park K, Elias PM, Oda Y, Mackenzie D, Mauro T, Holleran WM, et al. Regulation of cathelicidin antimicrobial peptide expression by an endoplasmic reticulum (ER) stress signaling, vitamin D receptor-independent pathway. J Biol Chem 2011;286:34121-34130.
57. Yamasaki K, Kanada K, Macleod DT, Borkowski AW, Morizane S, Nakatsuji T, et al. TLR2 expression is increased in rosacea and stimulates enhanced serine protease production by keratinocytes. J Invest Dermatol 2011;131:688-697.
58. Da Silva CA, Hartl D, Liu W, Lee CG, Elias JA. TLR-2 and IL-17A in chitin-induced macrophage activation and acute inflammation. J Immunol 2008;181:4279-4286.
59. Georgala S, Katoulis AC, Kylafis GD, Koumantaki-Mathioudaki E, Georgala C, Aroni K. Increased density of Demodex folliculorum and evidence of delayed hypersensitivity reaction in subjects with papulopustular rosacea. J Eur Acad Dermatol Venereol 2001;15:441-444. (Pubitemid 33040117)
60. Hollox EJ, Huffmeier U, Zeeuwen PL, Palla R, Lascorz J, Rodijk-Olthuis D, et al. Psoriasis is associated with increased beta-defensin genomic copy number. Nat Genet 2008;40:23-25.
61. Lande R, Gregorio J, Facchinetti V, Chatterjee B, Wang YH, Homey B, et al. Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide. Nature 2007;449:564-569. (Pubitemid 47525141)
62. Dombrowski Y, Peric M, Koglin S, Kammerbauer C, Göss C, Anz D, et al. Cytosolic DNA triggers inflammasome activation in keratinocytes in psoriatic lesions. Sci Transl Med 2011;3:82ra38.
63. Emelianov VU, Bechara FG, Gläser R, Langan EA, Taungjaruwinai WM, Schröder JM, et al. Immunohistological pointers to a possible role for excessive cathelicidin (LL-37) expression by apocrine sweat glands in the pathogenesis of hidradenitis suppurativa/acne inversa. Br J Dermatol 2011. [Epub ahead of print]
64. Gombart AF, Borregaard N, Koeffler HP. Human cathelicidin antimicrobial peptide (CAMP) gene is a direct target of the vitamin D receptor and is strongly up-regulated in myeloid cells by 1, 25-dihydroxyvitamin D3. FASEB J 2005;19:1067-1077. (Pubitemid 40946432)
65. Wang TT, Nestel FP, Bourdeau V, Nagai Y, Wang Q, Liao J, et al. Cutting edge: 1, 25-dihydroxyvitamin D3 is a direct inducer of antimicrobial peptide gene expression. J Immunol 2004;173:2909-2912. (Pubitemid 39141992)
66. Peric M, Koglin S, Dombrowski Y, Gross K, Bradac E, Büchau A, et al. Vitamin D analogs differentially control antimicrobial peptide/ "alarmin" expression in psoriasis. PLoS One 2009;4:e6340.
67. Reinholz M, Ruzicka T, Schauber J. Vitamin D and its role in allergic disease. Clin Exp Allergy 2011. [Epub ahead of print]
68. Hata TR, Kotol P, Jackson M, Nguyen M, Paik A, Udall D, et al. Administration of oral vitamin D induces cathelicidin production in atopic individuals. J Allergy Clin Immunol 2008;122:829-831.
69. Hartmann B, Riedel R, Jörss K, Loddenkemper C, Steinmeyer A, Zügel U, et al. Vitamin D receptor activation improves allergen-triggered eczema in mice. J Invest Dermatol 2012;132:330-336.
70. Vähävihu K, Ala-Houhala M, Peric M, Karisola P, Kautiainen H, Hasan T, et al. Narrowband ultraviolet B treatment improves vitamin D balance and alters antimicrobial peptide expression in skin lesions of psoriasis and atopic dermatitis. Br J Dermatol 2010;163:321-328.
71. Lazaridou E, Giannopoulou C, Fotiadou C, Vakirlis E, Trigoni A, Ioannides D. The potential role of microorganisms in the development of rosacea. J Dtsch Dermatol Ges 2011;9:21-25.
72. van Zuuren EJ, Gupta AK, Gover MD, Graber M, Hollis S. Systematic review of rosacea treatments. J Am Acad Dermatol 2007;56:107-115. (Pubitemid 44969302)
73. Del Rosso JQ, Webster GF, Jackson M, Rendon M, Rich P, Torok H, et al. Two randomized phase III clinical trials evaluating anti-inflammatory dose doxycycline (40-mg doxycycline, USP capsules) administered once daily for treatment of rosacea. J Am Acad Dermatol 2007;56:791-802. (Pubitemid 46561002)
74. Graupe K, Cunliffe WJ, Gollnick HP, Zaumseil RP. Efficacy and safety of topical azelaic acid (20 percent cream): an overview of results from European clinical trials and experimental reports. Cutis 1996;57(1 Suppl):20-35.
75. Yamasaki K, Gallo R. Azelaic acid gel 15% alters kallikrein 5 and cathelicidin expression in epidermal keratinocytes, critical elements in the pathogenesis of rosacea. J Am Acad Dermatol 2010;60:AB1.
76. Jansen T, Krug S, Kind P, Plewig G, Messer G. BsmI polymorphism of the vitamin D receptor gene in patients with the fulminant course of rosacea conglobata (rosacea fulminans). J Dermatol 2004;31:244-246. (Pubitemid 38478357)
77. Segaert S. Vitamin D regulation of cathelicidin in the skin: toward a renaissance of vitamin D in dermatology? J Invest Dermatol 2008;128:773-775. (Pubitemid 351374313)
78. Ganguly D, Chamilos G, Lande R, Gregorio J, Meller S, Facchinetti V, et al. Self-RNA-antimicrobial peptide complexes activate human dendritic cells through TLR7 and TLR8. J Exp Med 2009;206:1983-1994.
79. Lebwohl M, Menter A, Koo J, Feldman SR. Combination therapy to treat moderate to severe psoriasis. J Am Acad Dermatol 2004;50:416-430. (Pubitemid 38316135)
80. Kim SK, Park S, Lee ES. Toll-like receptors and antimicrobial peptides expressions of psoriasis: correlation with serum vitamin D level. J Korean Med Sci 2010;25:1506-1512.